DDR1
ENSG00000204580
Target class
Kinase
Chromosome
6
- Chemical probe available
- Yes
- Target name
- DDR1
- Gene name
- Discoidin domain receptor tyrosine kinase 1
- Gene symbol
- DDR1
- Protein name
- Epithelial discoidin domain-containing receptor 1 (Epithelial discoidin domain receptor 1) (EC 2.7.10.1) (CD167 antigen-like family member A) (Cell adhesion kinase) (Discoidin receptor tyrosine kinase) (HGK2) (Mammary carcinoma kinase 10) (MCK-10) (Protein-tyrosine kinase 3A) (Protein-tyrosine kinase RTK-6) (TRK E) (Tyrosine kinase DDR) (Tyrosine-protein kinase CAK) (CD antigen CD167a)
- RTK6
- CD167
- NTRK4
- PTK3A
- NEP
- CAK
- EDDR1
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|CD molecules|MicroRNA protein coding host genes
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 104.7
- Tissue specificity (Gini)
- 0.387
- Tissue specificity (tau)
- 0.651
- KEGG gene identifiers
- hsa:780
- Reactome pathways
- R-HSA-3000171
- Protein interaction confidence
- 0.7644
- Protein interaction partners
- 5
- End position
- 30900978
- Start position
- 30876421
- Chromosome
- 6
- Strand
- Forward
- [Isoform 1]: Cell membrane
- Single-pass type I membrane protein.
- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane
- Single-pass type I membrane protein.
- SUBCELLULAR LOCATION: [Isoform 3]: Secreted .
- SUBCELLULAR LOCATION: [Isoform 4]: Cell membrane
- Single-pass type I membrane protein.
- Plasma membrane
- Tissue specificity (tau)
- 0.651408
- Expression inequality (Gini)
- 0.387094
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)
- 104.7
- Esophagus - Mucosa
- 104.24
- Minor Salivary Gland
- 101.45
- Skin - Not Sun Exposed (Suprapubic)
- 96.61
- Skin - Sun Exposed (Lower leg)
- 90.41
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)104.7
- Esophagus - Mucosa104.24
- Minor Salivary Gland101.45
- Skin - Not Sun Exposed (Suprapubic)96.61
- Skin - Sun Exposed (Lower leg)90.41
- Thyroid90.05
- Vagina83.53
- Kidney - Medulla65.6
- Pituitary62.49
- Brain - Substantia nigra62.32
- Prostate60.92
- Breast - Mammary Tissue50.6
- Brain - Hypothalamus47.21
- Brain - Cortex44.22
- Ovary41.97
- Kidney - Cortex41.83
- Brain - Amygdala41.6
- Brain - Nucleus accumbens (basal ganglia)41.04
- Stomach40.21
- Nerve - Tibial39.85
- Brain - Caudate (basal ganglia)38.52
- Brain - Hippocampus38.27
- Colon - Transverse36.94
- Brain - Anterior cingulate cortex (BA24)35.74
- Small Intestine - Terminal Ileum34.49
And 29 more, listed on the interactive page.
- GO:0007155
- GO:0010715
- GO:0014909
- GO:0038063
- GO:0038083
- GO:0044319
- GO:0046777
- GO:0061302
- GO:0005576
- GO:0005886
- GO:0043235
- GO:0070062
- GO:0004714
- GO:0005515
- GO:0005518
- GO:0038062
Related records
Trials (378)
- 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
- A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.
- A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
- A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of Meformin
- A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
- A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
- A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
- A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
- A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
- A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
- A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
- A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults
- A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
- A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
- A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study
- A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
- A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
- A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
Drugs (5)
- Imatinib
- Merestinib
- Naporafenib
- Nilotinib
- Pralsetinib